Brief: Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil
31/03/2025 02:31
March 31 (Reuters) - Mesoblast Ltd MSB.AX: ENTERED INTO MEDICAID NATIONAL DRUG REBATE AGREEMENT WITH U.S. CMS FOR RYONCIL Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M